Research of inflation rate and its determinants: An analysis of GSK corporation in United States

meiyi, chen (2019): Research of inflation rate and its determinants: An analysis of GSK corporation in United States.

Abstract

With the rapid development of technology and the economy, more and more companies realized that the macroeconomic factors are quite important in terms of the big changes of them might carry the systematic risks to the whole system. For example, the subprime crisis happened in the United States in 2007 and eventually caused the financial crisis to the whole world. Therefore, this paper will choose the GSK corporation as the sample and analyze the inflation risk and the determinants of it. During this paper, the author used the inflation rate as dependent variables and ROA, ROE, corporate governance index, Tobin’s Q, Altman-Z score, GDP growth rate and the unemployment rate as the independent variables in order to find the relationship among these variables.

• Item Type: MPRA Paper
• Language: English
• Keywords: Inflation, GDP, Unemployment Rate
• Subjects: E - Macroeconomics and Monetary Economics > E2 - Consumption, Saving, Production, Investment, Labor Markets, and Informal Economy > E24 - Employment ; Unemployment ; Wages ; Intergenerational Income Distribution ; Aggregate Human Capital ; Aggregate Labor Productivity; E - Macroeconomics and Monetary Economics > E3 - Prices, Business Fluctuations, and Cycles

References

GlaxoSmithkline(15 feb,2019) Wikipedia, the free encyclopedia

Baidu,GlaxoSmithKline China Bribery（07,2013）

Agrawal, A., & Chadha, S. (2005). Corporate governance and accounting scandals. The Journal of Law and Economics, 48(2), 371-406.

Lajili, K., & Zéghal, D. (2010). Corporate governance and bankruptcy filing decisions. Journal of General Management, 35(4), 3-26.

Bhagat, S., & Bolton, B. (2008). Corporate governance and firm performance. Journal of corporate finance, 14(3), 257-273.

Dignam, A., & Galanis, M. (2008). Corporate governance and the importance of macroeconomic context. Oxford Journal of Legal Studies, 28(2), 201-243.

Smirlock, M., Gilligan, T., & Marshall, W. (1984). Tobin's q and the Structure-Performance Relationship. The American Economic Review, 74(5), 1051-1060.

Cohen, J. (1960). A coefficient of agreement for nominal scales. Educational and psychological measurement, 20(1), 37-46.

Oja, H. (1983). Descriptive statistics for multivariate distributions. Statistics & Probability Letters, 1(6), 327-332.

Weiss, N. A., & Hassett, M. J. (1999). Introductory statistics. Boston: Addison-Wesley.

Wigginton, J. E., & Abecasis, G. R. (2005). PEDSTATS: descriptive statistics, graphics and quality assessment for gene mapping data. Bioinformatics, 21(16), 3445-3447. Sims, C. A. (1980). Macroeconomics and reality. Econometrica: journal of the Econometric Society, 1-48.

Rode, S. (2012). Advanced macroeconomics. Bookboon.

BLANCHARD, O. A., Blanchard, O. J., & Fischer, S. (1989). Lectures on macroeconomics. MIT press.

Chung, K. H., & Pruitt, S. W. (1994). A simple approximation of Tobin's q. Financial management, 70-74.

Wernerfelt, B., & Montgomery, C. A. (1988). Tobin's q and the importance of focus in firm performance. The American Economic Review, 246-250.

Altman, E. I. (2000). Predicting financial distress of companies: revisiting the Z-score and ZETA models. Stern School of Business, New York University, 9-12

Calandro Jr, J. (2007). Considering the utility of Altman's Z-score as a strategic assessment and performance management tool. Strategy & Leadership, 35(5), 37-43.

ADAM, H. (2019). How the Q Ratio (Tobin's Q Ratio) Works. Retrieved from Bhagat, S., & Bolton, B. (2008). Corporate governance and firm performance. Journal of corporate finance, 14(3), 257-273.

Bradsher, H. (2010). Prius Brake Inquiry May Be Another Blow for Toyota. Retrieved

Billich, A. (2003). S-1360 Shionogi-GlaxoSmithKline. Current opinion in investigational drugs (London, England: 2000), 4(2), 206-209.

Garçon, N., Chomez, P., & Van Mechelen, M. (2007). GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert review of vaccines, 6(5), 723-739.

Nisen, P., & Rockhold, F. (2013). Access to patient-level data from GlaxoSmithKline clinical trials. New England Journal of Medicine, 369(5), 475-478.

Crabb, C. (2006). GlaxoSmithKline ends aplaviroc trials. Aids, 20(5), 641.

Evangelista, S. (2005). Talnetant GlaxoSmithKline. Current opinion in investigational drugs (London, England: 2000), 6(7), 717-721.

Gibson, L. (2004). GlaxoSmithKline to publish clinical trials after US lawsuit. BMJ: British Medical Journal, 328(7455), 1513.